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As the efficacy of postoperative chemotherapy for ovarian cancer
is closely related to the prognosis of patients, especially those with
advanced cancer, an important issue in the therapy for ovarian
cancers is to clarify the mechanisms of resistance to anti-cancer
agents. 
Cis-diamminedichloroplatinum (CDDP) and taxanes currently
are 2 of the most effective anti-cancer agents for ovarian cancer.
Currently, chemotherapy regimens for epithelial ovarian cancer
have been changed by the results of several clinical trials (Omura
et al, 1989; McGuire et al, 1996). However, platinum agents, such
as CDDP and carboplatin, still are used as a key-drug in regimens
for ovarian cancer. Therefore, understanding the mechanisms of
resistance to platinum agents may be helpful for improving the
prognosis of patients with advanced ovarian cancer. However, in
spite of many molecular biologic studies, such as the investigation
of multi-drug resistance (mdr) gene expression (Kusaba et al,
1999; Leith et al, 1999), the expression of glutathione-associated
enzymes (Nishimura et al, 1996; D’Incalci et al, 1998), and the
loss of p53 function (Bunz et al, 1999; Zheng et al, 1999), there is
no clear understanding about the mechanism of the resistance to
CDDP acquired during chemotherapy for ovarian cancer, and the
optimal management of CDDP-resistant ovarian cancer has yet to
be established. 
Generally, CDDP-based chemotherapy is administrated for 5 
or 6 courses for patients with ovarian cancer as induction
chemotherapy, if the residual tumour shows no obvious enlarge-
ment or no distant metastases appear during the first few cycles of
chemotherapy. Previous large clinical trials revealed that postoper-
ative CDDP-based chemotherapy could achieve a 60% response
rate (McGuire et al, 1996) with cyclophosphamide, a 73% response
rate with paclitaxel (McGuire et al, 1996), or a 69% response rate
(Muggia et al, 2000) with CDDP alone in patients with primary
epithelial ovarian cancer. However, the causative factor that
prevents improvements in the therapeutic efficacy for advanced
ovarian cancer is the acquired resistance to anti-cancer agents
including CDDP. The most well-known pattern of this acquisition
is that the early phase of chemotherapy fails to achieve a complete
remission but causes a partial reduction in the tumour size, and
then, with repeated administration of the CDDP-based
chemotherapy, the response of the tumour to the anti-cancer agent
decreases. Therefore it is essential to elucidate the mechanisms
responsible for the decreased responses of the tumour to anti-
cancer agents during the course of CDDP-based chemotherapy. 
Recent studies have suggested that an abnormality in the DNA
mismatch repair system, which has been reported to be the cause of
hereditary cancers such as hereditary nonpolyposis colorectal cancer
(HNPCC), may be involved in resistance to anti-cancer agents,
because the anti-cancer effects of chemotherapy are often dependent
upon the generation of DNA damage, which is recognized by the
DNA mismatch repair system (Fink et al, 1996; Karran and Hamps,
1996). In addition, recently reported in vitro (Anthoney et al, 1996)
and in vivo (Aebi et al, 1996; de las Alas et al, 1997) studies
revealed that one of the causative factors of this deficiency is a loss
of hMLH1 expression due to the hypermethylation of the promoter
for the hMLH1 gene (Strathdee et al, 1999; Plumb et al, 2000).
However, it is still unknown whether the microsatellite instability
(MSI) occurred as a result of a deficiency in the DNA mismatch
repair system before or after CDDP-based induction chemotherapy
in patients with advanced primary epithelial ovarian cancer.
Therefore, we conducted a comparative study on MSI and the
expression of the DNA mismatch repair-related proteins hMLH1
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and hMSH2 in primary resected tumours and residual tumours in
women requiring a second excision of ovarian cancer following 5 or
6 courses of CDDP-based postoperative induction chemotherapy to
manage an incomplete primary resection.
MATERIALS AND METHODS 
Subjects 
The subjects of this study were 24 patients with primary epithelial
ovarian cancer in whom the primary operation resulted in a noncu-
rative resection with residual tumours large enough to be
measured for the determination of the efficacy of post-operative
induction chemotherapy who were treated in our department from
1989 to 1995. Despite a total 5 or 6 courses of postoperative
CDDP-based chemotherapy, we performed secondary cytoreduc-
tive surgery at 6 to 8 weeks after the final administration of
CDDP-based chemotherapy for the cases with a partial response
(PR) and no change (NC). Those with a complete response (CR) or
progressive disease (PD) did not undergo secondary cytoreductive
surgery. Paired tumour samples from these 2 resections were used
to assess the effects of CDDP-based chemotherapy on the
tumour’s microsatellite instability (MSI) and the protein expres-
sion of hMSH2 and hMLH1. In this study, we obtained informed
consent from all patients prior to examine the specimens. 
The clinical stage of each patient was determined according to
the classification of the International Federation of Gynecology
and Obstetrics (FIGO, 1989). It was stage IIIc in 19 patients and
stage IV in 5 patients. The histologic subtypes included serous
adenocarcinoma (14 patients), serous papillary adenocarcinoma (3
patients), mucinous adenocarcinoma (1 patient), endometrioid
adenocarcinoma (3 patients), clear cell adenocarcinoma (2
patients), and undifferentiated carcinoma (1 patient). The histo-
logic grade was G1 in 4 patients, G2 in 16 patients, and G3 in 4
patients. 
The postoperative chemotherapy regimen was CAP (CDDP 
50 mg m–2, doxorubicin 40 mg m–2, cyclophosphamide
300 mg m–2), or CP (CDDP 70 mg m–2, cyclophosphamide 500 mg).
All patients received 5 or 6 courses of this regimen (mean: 5.5
courses), and the mean total dose of CDDP administrated was
427.7 ± 19.1 mg (range: 408–480 mg). The assessment of the
tumour’s response to chemotherapy was based upon the World
Health Organization criteria (1979) and was classified as a partial
response (PR) in 11 cases and no change (NC) in 13 cases. 
Preparation of samples 
The existence of cancer cells and their histologic subtype and
grade were confirmed using haematoxylin and eosin staining of
the samples obtained from tumour excised during the primary
surgery or the secondary surgery after chemotherapy. Sample
slices 4 µ m in thickness were prepared by microdissection from
the paraffin-embedded cancerous and normal tissues. DNA was
extracted using DEXPAT™ (Takara, Shiga, Japan) to prepare the
DNA templates for polymerase chain reaction (PCR). 
Assay for MSI 
As primers for the assay for MSI we used 10 microsatellite loci
which included BAT25, BAT26, BAT40, D2S123, D3S1612,
D5S346, D11S904, D17S795, D18S58, and TP53 (MAPPAIRS™;
Research Genetics, Huntsville, AL). Four loci (BAT25, BAT26,
D2S123, and D5S346) were recommended for analysing MSI, and
2 loci (BAT40 and D18S58) were recommended as alternative loci
as published in the International Guidelines for the Evaluation of
MSI in Colorectal Cancer (Boland et al, 1998). We selected 4 more
microsatellite loci including D3S1612 (hMLH1) (Hass et al,
1999), D11S904 (Hickey et al, 1999) (chromosome 11p),
D17S795 (Pieretti et al, 1995) (chromosome 17q), and TP53 (p53)
for the assay of MSI. The forward primer was 5′-end-labelled with
[γ 32P]-ATP (Amersham Pharmasia Biotech, Tokyo, Japan) using
T4-polynucleotide kinase (Promega, Madison, WI), and was used
together with an unlabelled reverse primer. 
For the PCR amplification of the microsatellite loci, 1 µ l of each
extracted DNA sample was used per 5 µ l reaction mixture
containing 1 × PCR buffer (Promega), 2 mM MgCl2, 250 µ M of a
dNTP mixture (Promega), 10 pmol each of the unlabelled reverse
primer and labelled forward primer, 0.25 unit of Taq DNA poly-
merase (Promega), and double distilled water. The PCR amplifica-
tion was performed in a thermal cycler (Perkin-Elmer Cetus,
Emeryville, CA) with the following cycling conditions: 2 min at
96˚C followed by 35 cycles of 94˚C for 45 s, 57˚C for 45 s and
72˚C for 60 s, for BAT25, BAT26, D2S123, D11S904, D17S795,
and TP53; and 10 min at 95˚C followed by 35 cycles of 94˚C for
30 s, 55˚C for 60 s and 72˚C for 60 s, for BAT40, D3S1612,
D5S346, and D18S58. After the final cycle, 7 min at 72˚C was
added for a final elongation step. 
After PCR amplification, the products were denatured at 94˚C
for 5 min, and analysed on 6% polyacrylamide gel (Bio-Rad,
Hercules, CA) containing 7 M urea (Wako Pure Chemical, Osaka,
Japan). After electrophoresis, the MSI and the loss of hetero-
zygosity (LOH) were confirmed using a Bio-Imaging Analyzer
(BAS 1000; FUJIX, Tokyo, Japan) by comparing the microsatel-
lite loci of normal tissue and those of the cancerous tissue. LOH
was defined as > 50% visible reduction of the band intensity of
one allele of the tumour sample compared with the corresponding
normal tissue sample (Pieretti et al, 1995). 
Definition of the MSI 
The cases in which there were 7 or more informative loci out of a
total of 10 loci examined were used to judge MSI. If an allelic shift
between the normal DNA and the cancerous DNA was found in at
least one of the products of each of the 10 microsatellite loci exam-
ined, it was scored as an MSI tumour. If the MSI was confirmed in
1 or 2 microsatellite loci (<30%), it was scored as MSI-L, while if
MSI was confirmed in 3 or more microsatellite loci (≥ 30%), it was
scored as MSI-H according to the criteria of a prior report (Boland
et al, 1998). 
Immunohistochemical staining 
The same paraffin-embedded cancer tissues as those used for the
MSI analysis were sectioned into 4-µ m-thick slices and examined
for the expression of hMSH2 and hMLH1 by immunohistochem-
ical staining using anti-hMSH2 and hMLH1 antibodies and a
VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA).
For the staining of hMSH2 and hMLH1, we used anti-hMSH2
(Santa Cruz Biotechnology, Santa Cruz, CA) and anti-hMLH1
(Santa Cruz Biotechnology). To confirm the positivity for hMSH2
and hMLH1 expression, staining without either of the primary
antibodies served as a negative control. Two slides in each sample
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pendent pathologist who was completely blinded to treatment
status and patients name. In scoring the immunostained slides, the
stain intensity of cancer cells was graded: no staining, weakly
positive, and strongly positive, and the percentage of cancer cells
that stained positively was also graded: 0–20%, 20–80% and
80–100%. If no staining or weakly positive staining were
observed, and the percentage of stained cells were less than 20%,
we decided that the expression of hMLH1 or hMSH2 was scored
undetectable by the immunohistochemical staining. 
Statistical analysis 
We used an exact probability test and signed rank test for statistical
analysis. A P value less than 0.05 was regarded as statistically
significant. 
RESULTS 
MSI and expression of hMSH2, hMLH1 protein in the
primary resected tumours 
MSI was detected in 37.5% (9/24) of the primary resected tumours
before CDDP treatment while 15 cases were judged as MSS. 5
cases showed MSI in only 1 microsatellite loci (2 cases had MSI in
D5S346, 2 cases had MSI in BAT26, and 1 case had MSI in
D2S123), 2 cases had MSI in 2 microsatellite loci (1 case had MSI
in BAT25 and D18S58, 1 case had MSI in BAT40 and D2S123), 1
case had MSI in 3 microsatellite loci (BAT26, BAT40 and
D18S58), and 1 case had MSI in 4 microsatellite loci (BAT25,
BAT26, D3S1612 and TP53). Of the tumours which were initially
positive for MSI, 77.8% (7/9) were scored as MSI-L and 22.2%
(2/9) as MSI-H. 
Concerning the expression of hMSH2 and hMLH1 in the
primary resected tumours, of the 9 primary resected tumours 
that were positive for MSI, 4 (44.4%) were undetectable for
hMSH2 expression, 3 (33.3%) were undetectable for hMLH1
expression, and 2 (22.2%) were positive for both hMSH2 and
hMLH1 expression. The 15 primary resected tumours that were
MSS were all positive for both hMSH2 and hMLH1 expression
(Table 1). Moreover, LOH was confirmed in 8 (33.3%) of the
primary resected tumours. The most frequent LOH loci was TP53
(6/8; 75%), and the histologic subtype of the TP53 LOH cases
were serous adenocarcinoma or serous papillary adenocarcinoma.
Moreover, none of the LOH cases exhibited a change in the LOH
loci or the number of LOH loci in the secondary resected residual
tumors after CDDP-based chemotherapy. 
MSI and expression of hMSH2, hMLH1 protein in the
secondary resected residual tumours after CDDP-
based chemotherapy 
All the tumours which were initially positive for MSI were also
positive for MSI after CDDP-based chemotherapy. One case had an
increase in the number of MSI loci, and 2 initially positive hMLH1
cases became undetectable for hMLH1 expression (Table 2).
Moreover, to our surprise, we found that 15 of the 15 (100%)
primary tumours which were negative for MSI become positive
for MSI (P < 0.001) after CDDP-based chemotherapy (2 cases
changed to MSI-L, and 13 cases changed to MSI-H). In addition,
there was a significant difference (P < 0.001) in the mean number
of loci with MSI during CDDP-based chemotherapy (before, 0.0 ±
0.0; after, 3.9 ± 1.4). Furthermore, the change in the expression of
the hMLH1 protein to undetectable in 10 of the 15 (66.7%)
secondary resected tumours after CDDP-based chemotherapy was
statistically significant (P < 0.001) (Table 3). 
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Table 1 Clinicopathologic characteristics of the study subjects with primary ovarian cancer 





Serous adenocarcinoma 14 
Serous papillary adenocarcinoma 3 
Endometrioid adenocarcinoma 3 
Clear cell adenocarcinoma 1 
Mucinous adenocarcinoma 1 








Mean treatment courses (range) 5.5 ± 0.5 (5 – 6) 




Stage was according to FIGO 1989 classification. CAP: cisplatin (CDDP) 50 mg m–2 + doxorubicin
40 mg m–2 + cyclophosphamide 300 mg m–2, CP: cisplatin 70 mg m–2 + cycrophosphamide 500 mg.
Therapeutic effect was graded using WHO criteria. 
BJOC 01-2037 1064-1069  1/10/01  11:39 am  Page 1066MSI of ovarian cancer by CDDP-based chemotherapy 1067
British Journal of Cancer (2001) 85(7), 1064–1069 © 2001 Cancer Research Campaign
DISCUSSION 
In primary epithelial ovarian cancer, the percentage of tumours
positive for MSI has been reported to be no more than 12%
(Arzimanoglou et al, 1996) to 26% (Codegoni et al, 1999), and
even in ovarian cancers without MSI, it is uncommon to experi-
ence little or no tumour reduction with CDDP treatment.
Therefore, it is difficult to predict a tumour’s resistance to CDDP
solely by the presence or absence of MSI in the primary tumour.
An important issue in resistance to CDDP-based chemotherapy is
the acquired resistance due to genetic mutations in cancer cells
during the course of chemotherapy. This obviously would lower
the efficacy of the chemotherapy against ovarian cancer, and
remains a serious obstacle for improving the prognosis of patients
with ovarian cancer. Therefore, it is important to elucidate the
mechanisms involved in the changes in the characteristics of
cancer cells caused by CDDP-based chemotherapy. The present
study revealed that of the 9 patients whose primary tumour
samples were positive for MSI, only 1 achieved a PR with a 52%
reduction of the residual tumour, while the other 8 cases had a
reduction of less than 50% or even tumour growth. Furthermore,
in the comparative study of primary resected tumours and
secondary resected residual tumours, we found that all of the MSS
tumours changed to MSI tumours during CDDP-based
chemotherapy, and 87% of these MSS tumours which had a
change in their microsatellite status became MSI-H tumours. In
the present study we did not identify the mechanism responsible
for the loss of hMLH1 expression, but the possibility that changes
in hMLH1 gene expression could occur during CDDP-based treat-
ment is strongly suggested by our results since all of the residual
tumours become positive for MSI. In these tumours, the expres-
sion of hMSH2 remained stable while the expression of hMLH1
became undetectable in the 67% of the tumours after CDDP-based
treatment. Furthermore, even in the patients whose resected
primary tumour was positive for MSI, 2 of the residual tumours
also become undetectable for hMLH1 expression after CDDP-
based treatment. These data suggest that CDDP-based treatment
does not have an effect on the expression of hMSH2 but it does
affect hMLH1, and this mechanism may be the major cause of the
differences in MSI between a primary resected tumour and the
residual tumour during CDDP-based treatment. Fink et al (1998)
examined 38 paired tumour samples from patients with ovarian
cancer before and after CDDP or carboplatin-based chemotherapy,
and reported that 66% of the cases demonstrated a reduction of
Table 2 Microsatellite status and the expression of hMSH2, hMLH1 in the residual tumours of microsatellite stable primary ovarian carcinoma after CDDP-
based chemotherapy 
Case no Examined microsatellite loci
hMSH2 hMLH1   
BAT25 BAT26 BAT40 D2S123 D3S1612 D5S346 D11S904 D17S794 D18S58 TP53 expression expression
1      ΟΟ   Ο   Ο   +N  
2 ΟΟ   ΟΟ ΟΟ ΟΟ   +N  
3    ΟΟ Ο   ×Ο LOH Ο +N  
4 Ο    Ο    LOH Ο× LOH + N 
5 ΟΟ   ΟΟ    Ο    +N  
6      Ο LOH    Ο    +N  
7   ΟΟ Ο Ο× Ο   Ο   ++  
8 Ο   Ο    Ο   ΟΟ Ο ++  
9   ΟΟ Ο   ΟΟ ΟΟ LOH + N 
10      ΟΟ   ΟΟ Ο Ο ++  
11    ΟΟ × Ο Ο   ΟΟ +N  
12   Ο   Ο    ΟΟ Ο LOH + N 
13 Ο    ΟΟ   ΟΟ Ο Ο +N  
14   ΟΟ   Ο   ΟΟ Ο   ++  
15 Ο   ΟΟ    ΟΟ ×   ++  
Ο = negative for allelic shift;   = allelic shift has changed from negative to positive; × = not amplified; LOH = loss of heterozygosity; + = positive expression; 
N = expression has changed from positive to undetectable. 
Table 3 Microsatellite status and the expression of hMSH2, hMLH1 in the residual tumours of microsatellite unstable primary ovarian carcinoma after 
CDDP-based chemotherapy 
Case no Examined microsatellite loci
hMSH2 hMLH1   
BAT25 BAT26 BAT40 D2S123 D3S1612 D5S346 D11S904 D17S794 D18S58 TP53 expression expression
16 Ο   ΟΟΟ   ΟΟ Ο LOH + N 
17    ΟΟ    ΟΟ Ο LOH – N 
18 Ο   ΟΟΟ Ο LOH ΟΟ Ο –+  
19 ΟΟΟ Ο Ο   ΟΟ × LOH + – 
20 Ο    ΟΟΟΟΟ   Ο +–  
21 ΟΟΟ   ΟΟΟΟ Ο Ο +–  
22 ×ΟΟ Ο Ο   ΟΟ Ο Ο –+  
23   Ο × ΟΟΟΟΟ   Ο –+  
24 ΟΟ    ΟΟΟΟ Ο × ++  
Ο = negative for allelic shift;   = positive for allelic shift;   = allelic shift has changed from negative to positive; × = not amplified; LOH = loss of heterozygosity; 
+ = positive expression; – = undetectable; N = expression has changed from positive to undetectable. 
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hMLH1 expression after at least 3 cycles of platinum-based
chemotherapy. Mackay et al (2000) also analysed the expression of
MLH1 and p53 in 29 paired tumour samples from patients
with node-positive breast cancer before and after neoadjuvant
chemotherapy that included doxorubicin, epirubicin or CDDP.
They reported that the expression of MLH1 significantly
decreased after chemotherapy both in terms of the percentage of
MLH1-positive cells as well as the staining intensity of the posi-
tive cancer cells compared with the specimens obtained before
chemotherapy. On the other hand, the expression of p53 did not
change after the chemotherapy. Moreover, it was found that the
reduction of MLH1 expression after chemotherapy was correlated
significantly with a poorer disease-free survival of the patients.
They concluded that MLH1-staining status is one of the clinico-
pathologic prognostic factors in patients with node-positive breast
cancer. Samimi et al (2000) also analysed the expression of
hMLH1 and hMSH2 in paired ovarian tumour sections from 54
patients with ovarian cancer before and after platinum-based
neoadjuvant chemotherapy, and reported that both the expression
of hMLH1 and hMSH2 staining were decreased significantly after
platinum-based chemotherapy. However, they concluded that
immunohistochemical staining for either hMLH1 or hMSH2 was
not highly predictive of drug sensitivity as measured by response
or survival in patients with ovarian cancer while it was unclear
what the mean administered doses of CDDP, carboplatin, doxoru-
bicin or epirubicin were, and the microsatellite status of the
primary tumours were, these 2 recent studies concluded that the
expression of hMLH1 is reduced after chemotherapy, although
they reached conflicting conclusions regarding the role of hMLH1
reduction on the patient’s prognosis. Unexpectedly, our present
results regarding the expression of hMLH1 and the hMSH2 after
CDDP-based chemotherapy are somewhat contrary to the results
of Samimi et al (2000). All of our ovarian cancer patients received
5 or 6 courses (mean: 5.5 courses) of CDDP-based chemotherapy,
with a total CDDP dose of at least 400 mg (mean: 427.7 mg) for
induction chemotherapy for patients with ovarian cancer. Two
possibilities regarding the expression of hMLH1 and the hMSH2
after chemotherapy with platinum or alkylating agents may
explain these conflicting results: CDDP-based chemotherapy
affects both the expression of hMLH1 and hMSH2 during the
early treatment courses, because the crosslinking of the DNA
strands by the platinum therapy occurs randomly in each DNA
strand. However, as the treatment continues, only hMLH1 remains
inactive while the expression of hMSH2 recovers. Another possi-
bility is that CDDP-based chemotherapy could affect the expres-
sion of hMLH1 and the hMSH2 in both MSS and MSI tumours.
However, the effect to hMLH1 expression by CDDP-based
chemotherapy will be more frequently observed in the tumours
with normal DNA mismatch repair systems. 
5 or 6 courses of CDDP-based chemotherapy are standard for
patients with ovarian cancer if the tumour does not progress. Loss
of sensitivity to the CDDP-based chemotherapy generally occurs
after 3 or 4 courses of treatment, and the decision regarding
second-line chemotherapy for the relapsed ovarian tumour after
CDDP-based treatment depends on whether the relapsed tumour is
clinically resistant or sensitive to CDDP-based chemotherapy, was
determined by the platinum-free interval. The response rates of
recurrent tumours after platinum-based chemotherapy to further
platinum-based therapy depends on whether the relapse occurs
within or after 6 months from the final administration of the platinum
therapy (Ozols, 1997). Therefore, this suggests that CDDP-based
chemotherapy may not cause a permanent change in the genetic
characteristics on the residual tumour, and that perhaps the acquired
resistance of the residual tumour might occur during the late phase
of the CDDP-based chemotherapy. We suspect that the reduction of
hMLH1 or hMSH2 expression during the early phase of the
CDDP-based chemotherapy occurred as a defence mechanism of
the cells against DNA-toxic agents, but that the reduction of
hMLH1 expression after 5 to 6 courses of therapy might be the
final result of acquired resistance to CDDP-based chemotherapy.
This reduction in hMLH1 expression might have caused the MSI
of the residual tumour after CDDP-based chemotherapy. Perhaps
this acquired resistance develops when a residual tumour has
long-term, decreased expression of hMLH1 which then affects
the status of MSI, since our results were observed in patients
who did not achieve a complete remission with CDDP-based
chemotherapy. 
A recent study (Allen et al, 2000) has reported that MSI is not a
frequent event in ovarian cancer whereas LOH is found frequently,
and this result suggests that LOH might be more important in the
carcinogenesis of ovarian cancer. Our present study only evaluated
patients who had primary surgery and then had another operation for
the resection of their residual tumours after CDDP-based treatment;
the incidence of MSI (37.5%) in these patients was slightly higher
than that of LOH (29.2%). Furthermore, all LOH cases were serous-
type adenocarcinoma, and no LOH cases were found among those
with endometrioid adenocarcinoma, mucinous adenocarcinoma, or
clear cell adenocarcinoma, while MSI was found in 5 cases (55.6%)
of serous-type adenocarcinoma, 2 cases (22.2%) of endometrioid
adenocarcinoma, and 1 case each of mucinous adenocarcinoma and
clear cell adenocarcinoma based upon the 10 microsatellite loci
examined. These data suggest that the microsatellite loci examined
in this study were more suitable for determining MSI than LOH in
sporadic-type ovarian cancers. Moreover, the LOH cases had no
change either in the number of LOH loci or the location of LOH on
the chromosomes, while the MSI status changed in all of the MSS
tumours. Our results suggest that the CDDP-based treatment
affected only a tumours MSI and not its LOH, at least for patients
with relatively poor prognosis tumours.
If a resected primary ovarian cancer is positive for MSI or MSI
is acquired during CDDP-based treatment, anti-cancer agents
which are effective in the presence of a deficiency in DNA
mismatch repair should be used in the second-line chemotherapy
regimens. Although a screening test for various anti-cancer agents
using a DNA mismatch repair deficient cell line has been reported
and may help in the selection of anti-cancer agents for tumours
which have genetic instability (Fink et al, 1998), it seems likely
that it will be necessary to develop new anti-cancer agents that are
more effective against DNA mismatch repair deficient cells to
improve the prognosis of patients with advanced ovarian cancer.
The results of our present study also might provide the rationale
for gene therapy for advanced ovarian cancer by introducing a
functional hMLH1 gene into residual tumours after chemotherapy
to maintain sensitivity to CDDP. 
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